Clinical Trial

A Study of PLH-2301 in Subjects With Sarcopenia

Study acronym: PLH-2301_P2
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of PLH-2301 in subjects with sarcopenia. Eligible subjects aged 65 years and older will be randomized to receive placebo or one of three dose levels of PLH-2301 once daily for 12 weeks. The primary objective is to assess the effect of PLH-2301 on physical function compared with placebo.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-13
Trial Details
NCT Number NCT07390552
Lead Sponsor Pluto Inc.
Collaborators: Symyoo
Conditions Sarcopenia in Elderly
Enrollment 168 participants
Start Date 2026-05-08
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-12